Main article: South African Progress Report

By Theo Smart

“If we continue at the current rate, it’s going to take years and years before we get anywhere near the number of people on [antiretroviral] treatment that we need to,” Dr. Francois Venter of the University of the Witwatersrand (Wits) warned the audience on the final day of the 2nd South African AIDS Conference in June. He told conference-goers that the South African HIV treatment programme would have to scale up much more rapidly “to attain the target that we set for ourselves within the department. We need to work harder, faster, better, smarter to make this programme work.”

Dr. Venter, Clinical Director of the Esselen Street Project in Johannesburg, has participated in the National and Provincial Department of Health's ARV rollout working groups and supports the Gauteng and North-West Provinces in both training and treatment. He offered conference-goers a progress report on the implementation of South Africa’s “Comprehensive Plan for the Management of HIV and AIDS” as well as his insight into some of the challenges to more rapid rollout of antiretrovirals (ARVs).

First though, Dr. Venter took issue with the term ‘rollout’: “When you talk about diabetes, you don’t talk about the insulin “rollout” — it’s a ridiculous concept. And the ARV rollout is a cliché that I hope is going to die away… We’re going to talk about the package of care for HIV-infected people which will have all the components [contained in the comprehensive plan].”

“On behalf of all the clinicians here, none of us believe that antiretrovirals are the be all and end all,” said Dr. Venter. The comprehensive plan covers management over the entire course of the HIV disease from infection through the 8-10 years (on average) before advanced disease and progression to AIDS — “at which point,” said Dr. Venter “we need antiretroviral therapy.”

“There are a whole range of interventions that can slow that progression, which includes wellness — nutrition, exercise, stop smoking, safe sex, improving mental health, and decreasing the intake of alcohol. We only introduce the drugs right at the end.”

Even so, Dr. Venter believes that antiretrovirals work dramatically well when they are needed: “There are very few interventions in medicine that take someone who is essentially a skeleton and turn them back into being a fully functional, working human being.” He presented preliminary data from a few of the treatment sites in South Africa demonstrating that treatment was achieving dramatic CD4 and viral load responses, and that toxicity has been, for the most part, manageable. Dr. Venter thinks these responses will be sustained for quite some time. “Even using just the existing [marketed] drugs, the latest modelling suggests we are looking at more than twenty years [additional lifespan] on this package of care. That means these people will see their grandchildren — it’s a major medical miracle — exactly like insulin for diabetes.”

“If we provide all the support systems for comprehensive care, we are looking at a group who will grow old with HIV.”

“If we continue at the current rate, it’s going to take years and years before we get anywhere near the number of people on [antiretroviral] treatment that we need to,” Dr. Francois Venter of the University of the Witwatersrand (Wits) warned the audience on the final day of the 2nd South African AIDS Conference in June. He told conference-goers that the South African HIV treatment programme would have to scale up much more rapidly “to attain the target that we set for ourselves within the department. We need to work harder, faster, better, smarter to make this programme work.”

Dr. Venter, Clinical Director of the Esselen Street Project in Johannesburg, has participated in the National and Provincial Department of Health's ARV rollout working groups and supports the Gauteng and North-West Provinces in both training and treatment. He offered conference-goers a progress report on the implementation of South Africa’s “Comprehensive Plan for the Management of HIV and AIDS” as well as his insight into some of the challenges to more rapid rollout of antiretrovirals (ARVs).

First though, Dr. Venter took issue with the term ‘rollout’: “When you talk about diabetes, you don’t talk about the insulin “rollout” — it’s a ridiculous concept. And the ARV rollout is a cliché that I hope is going to die away… We’re going to talk about the package of care for HIV-infected people which will have all the components [contained in the comprehensive plan].”

“On behalf of all the clinicians here, none of us believe that antiretrovirals are the be all and end all,” said Dr. Venter. The comprehensive plan covers management over the entire course of the HIV disease from infection through the 8-10 years (on average) before advanced disease and progression to AIDS — “at which point,” said Dr. Venter “we need antiretroviral therapy.”

“There are a whole range of interventions that can slow that progression, which includes wellness — nutrition, exercise, stop smoking, safe sex, improving mental health, and decreasing the intake of alcohol. We only introduce the drugs right at the end.”

Even so, Dr. Venter believes that antiretrovirals work dramatically well when they are needed: “There are very few interventions in medicine that take someone who is essentially a skeleton and turn them back into being a fully functional, working human being.” He presented preliminary data from a few of the treatment sites in South Africa demonstrating that treatment was achieving dramatic CD4 and viral load responses, and that toxicity has been, for the most part, manageable. Dr. Venter thinks these responses will be sustained for quite some time. “Even using just the existing [marketed] drugs, the latest modelling suggests we are looking at more than twenty years [additional lifespan] on this package of care. That means these people will see their grandchildren — it’s a major medical miracle — exactly like insulin for diabetes.”

“If we provide all the support systems for comprehensive care, we are looking at a group who will grow old with HIV.”

Numbers

“At the moment there has been a lot of discussion about the numbers,” said Dr. Venter. Indeed, on the opening day of the conference, the Minister of Health Manto Tshabalala-Msimang had told the conference that the treatment programme was “on track,” but that she had no reliable figures on the actual delivery of services at the clinic level (at present around 50,000 South Africans are receiving antiretroviral treatment through the public sector).

She took issue with the World Health Organization’s (WHO) complaint that South Africa wasn’t reaching its share of the 3x5 targets (see http://www.aidsmap.com/en/news/77C1AB07-282C-4658-94BB-BD6F3C8BACE8.asp, http://www.aidsmap.com/en/news/545DE501-06E1-4DB8-91E4-14853F0BF7D0.asp) saying that “we were not consulted” when WHO set its goals. She also made reference to the Treatment Action Campaign (TAC) call to put many more people on treatment by 2006: “I see placards distributed today that people are aiming at 200,000 by 2006 and yet these figures have not been discussed with the Department of Health.”

And yet, Dr. Venter pointed out, this very figure had already been set as a target by the Department of Health in its comprehensive plan in October 2003, which noted that 5 million HIV-infected people needed care across the nation and 400-500,000 people needed antiretroviral treatment immediately. Page 79 of the plan says: “the team believes that the 50% ARV scenario is — at least in the early years of implementation — a more realistic forecast of both the likely uptake and of implementation capacity for a national ART programme.”

“50% is a realistic target of what we should be shooting for. We need to reassess that target from time to time, [but for now] the plan says that we should try to get half of the people on treatment as soon as possible,” said Dr. Venter. But at the current rate of scale up, “it will still take years to reach that 50%, somewhere around 200,000 and 300,000 patients (see Figure 1) — and one of the worrying things is that the monthly rate at which people are initiating antiretrovirals has actually gone down a bit during the last couple of months.”

Figure One

Dr. Venter presented the most recent available data on the numbers on treatment by province (see Figure 2) but noted that “looking at absolute numbers in each province isn’t really very useful.” He believes a better measure would be to look at the ratio of patients on treatment and the patients in need of treatment. Nevertheless, the numbers show that “there are provinces that are not scaling up as quickly as we would like and we really need to figure out why.”

Figure Two

Although recently, the Free State has seen a dramatic increase in the number of patients on treatment, in the early days of the rollout in that province, more than half the people who were staged for CD4 count and who qualified for treatment were lost to the programme before starting ART (see Figure 3) “Its a terrible thing,” said Dr. Venter “half the people — with upfront staging and when the green light has been given — are not getting into the programme.”

Figure Three

Barriers to more rapid scale-up and other threats to the programme

Adherence overkill

“While I do think we need to prepare patients for treatment, we are seeing adherence overkill especially in some of the rural provinces,” said Dr. Venter. He believes that some sites or provinces are getting too hung up on patient-readiness training, in an effort to ensure treatment adherence. Too much of this good thing could be scaring patients off.

During an earlier conference presentation, Dr. Norbert Ndjeka — who delivers ART treatment through a small primary health clinic in Bela Bela, Limpopo — noted that there are also long waiting times for adherence counseling, partly because clinics lack adequate physical space.

The first-wave effect

Dr. Venter also thinks that it isn’t realistic to expect the near perfect adherence that has been reported among some of the first African patients who have accessed ART. “One thing I disagree with very strongly is that Africans are better than people in the West at taking drugs. The people who are in the treatment programme at the moment are desperate for therapy — they are the first wave. The real patients are going to be seen in about three or four years time. We are not going to get the same level of adherence from them so I’m worried that we are holding up too high a bar in terms of people staying in the programme and adherence rates. We don’t need to expect the same level of adherence -- it’s just not practical.”

The superhuman syndrome

In general Dr. Venter believes that some sites may be setting the bar too high for patients: “The other thing I’m worried about is the superhuman syndrome. Before they are given antiretrovirals, patients are being told that they need to eat properly, stop smoking, disclose their status, exercise, stop drinking and think positively... and all before the next clinic visit. I look at that and I need a drink contemplating it myself. I don’t think that stopping people smoking is the priority... it’s something that we need to work on as clinicians but it shouldn’t be an obstacle to receiving ART.”

The R79 clinic access fee in Gauteng Province

Although antiretroviral treatment is free, patients attending hospital clinics in Gauteng (which includes Johannesburg and Pretoria) are required to pay a 79 Rand access fee to the clinic in order to get the antiretrovirals. There is no clinic access fee in other provinces.

“If you make it free,” said Dr. Venter “adherence improves.”

Human resources

“Human resources are a massive problem. I think one of the biggest problems in some of the provinces is that they are waiting until they have staffing to do this... unfortunately, the people do not exist.”

Mpumalanga and Limpopo, in the remote rural Northeast of the country, have been using this as an excuse to delay the rollout. Said Dr. Venter “I know lots of hospitals in Limpopo and Mpumulanga that have trained, committed staff, who haven't been 'authorised' [to use antiretrovirals].” Many people in these provinces also live far from tertiary hospitals so most treatment will ultimately have to be distributed at the primary healthcare level — which will never have adequate staffing to become fully accredited. According to Dr. Ndjeka’s presentation, Limpopo only intends to officially rollout treatment through its primary health clinics in 2008 — even though his clinic has provided an model by successfully treating hundreds of patients in Bela Bela.

According to Dr. Venter, “some of the most successful provinces, are the provinces who said that ‘we are never going to get enough people — we’ve been trying for years before the antiretroviral programme, we’re not going to get them now (more below).”

– Lack of pharmacists

Even so, be believes that a lack of qualified pharmacists is a major obstacle for the programme

– Dietitians: false obstacle?

But Dr. Venter believes that some of the human resource challenges are false obstacles, for example, the Comprehensive Plan’s requires that each ART site have a dietitian before it is accredited to dispense ART.

“I don’t understand this obsession with getting a dietitian,” said Dr. Venter. “when — for the diabetes programme — we often have situations where people are given dietary advice by nurses and counsellors who don’t necessarily have a dietary degree.”

– Retaining nurses

Dr. Venter quoted Dr. Herman Reuter, head of Medecin Sans Frontier's project in Lusikisiki, Eastern Cape. “What do we need to do to retain nurses in Lusikisiki? Build a city.”

Unfortunately, there are some areas of the country where it is difficult to lure and retain medical staff. Dr. Reuter serves as the sole medical doctor, managing a number of rural primary health clinics — each staffed with just one nurse — that are, nevertheless, successfully treating patients with ART in the Eastern Cape.

Voluntary counselling and testing

A heated debate at the conference concerned the question of whether or not to move towards a system of routine HIV testing in which anyone visiting a clinic would be routinely tested for HIV — unless they specifically asked not to be (opting out). Whilst not taking sides, Dr. Venter said “as a clinician I want to get people [early in infection] and not only when they are sick. As a selfish clinician I want the benefits to extend to the healthy to the unworried well. At the very least, there should be more 'active case finding' with VCT offered more aggressively to those diagnosed with TB or sexually transmitted diseases.”

Poor accrual of children

“The paediatric numbers are a disaster in some of the provinces. Clinicians are terrified by children — and they are more complicated than adults to treat.

Lab work

The scale-up of the ART-related (CD4 and viral load) laboratory services in South Africa has been very successful in most of the country. However, there are some areas where turn-around times are still too long. But the biggest lab-related challenges are limited access to other types of diagnostic tests — and the fact that CD4 and viral load test results are not being acted upon in a timely fashion (as in the Free State example).

Stock outs

“We’ve had shortages of drugs in several provinces and that is a disaster,” said Dr. Venter. “You can’t scream at patients and yell and moan about adherence when in fact, you can’t get your act together to buy the drug in time.”

Overcoming the obstacles

Dr. Venter provided a number of examples where scale up has occurred more rapidly. He credits much of the success of several projects to Dr. Pierre Barker and the Institute for Healthcare Improvement (IHI), which is working to improve the efficiency and quality of care provided by ART programme in five provinces. “His model is partly the reason for the dramatic upscaling in [these sites],” said Dr. Venter. “Pierre uses data on-site to improve service delivery, and empowers local managers to implement progressive changes in the clinic - small ones that slowly improve the system.”

Figure 4

Set a target

Dr. Venter and his colleagues at Johannesburg Hospital worked out that they needed to get about 10,000 people [8-12,000 within the hospital’s catchment area] on treatment. “At the beginning of February,” said Dr. Venter, “we only had about 2000 people on treatment and we were only putting approximately 80 patients per month on treatment. We worked out that we needed to get 400 on treatment each month [to reach our target in a reasonable time]. Just having that data in front of us we we’ve gone from 80 to about 170, 180 in just a few of months.”

Systems management (improving clinic efficiency to free up capacity)

Dr. Venter said that the Harriet Shezi Children’s Clinic did exactly the same thing, by working out how many children they needed to get on treatment per month to deal with the paediatric population at Chris Hani Baragwanath Hospital. Then, working with IHI, the clinic team assessed how it was delivering care — systems, workflows, etc — and how they would improve on it. By improving efficiency within the clinic itself (more efficient patient streaming, more effective consultations), the clinic has more than doubled its capacity to start new patients on therapy.

Active case finding

The freed up capacity at the paediatric clinic has allowed the staff to start actively looking for patients to be referred into the service from the inpatient ward. “Once they set themselves this target they went out trying to actively accrue that number of patients from within the Baragwanath system. And now they are steadily getting towards where they need to be.”

Accountable project leaders

Dr. Venter says that the Northwestern Province is another relatively recent success, which he attributes to “very driven and accountable project leaders, who are set targets, and given significant power to implement these,” according to Venter. “Also, there is very little of the 'can't do anything till everything is perfect' attitude you get in other provinces. Northwestern Province says ‘get on with it.’ They said ‘we are going to do the very best we can with the resources we are given.’ But despite having virtually no resources... they probably have the best ratio of patients on ARV therapy to the patients in need of therapy.”

For example, Taung Hospital in rural Northwestern Province has one of the fastest growing ART sites in the country. The hospital has six associated clinics that feed HIV-positive patients into the ART site. Within six months of opening, the site put 12% of the local patients in need of therapy on treatment -- at that rate, within 18 months the site should reach about half the patients in need of treatment. Dr. Venter credits “the people driving the programme, implementing it in the [provincial] department of health. The commitment of people like that, and the passion behind it is what makes for a good programme.”

Specialty clinics

Another challenge for the rollout in South Africa has been getting pregnant women who need ART for their own health into “rollout” sites before childbirth. Dr. Vivian Black and colleagues at the Reproductive Health Research Unit (RHRU) of the University of Witwatersrand have taken a completely different approach by simply setting up a pilot ART clinic within the obstetrics department of an antenatal clinic. So far, this project has placed 184 women onto treatment. “The pregnancy clinic is fascinating,” said Dr. Venter. “Site an ARV clinic in an easy-to-access group, and initiate them!”

Down referral — chronic care at the primary healthcare level

Ultimately, Dr. Venter said, South Africa must move away from hospital run programmes and start treating HIV like any other chronic condition — in primary healthcare clinics (such as those run by Dr. Ndjeka and Dr. Reuter).

The INI-associated projects have begun this process by down-referring patients who are stable on ART to local primary healthcare clinics — in order to keep patient numbers manageable. For example, the Harriet Shezi Children’s Clinic has begun to involve two primary health care clinics to provide long term nurse-based care and follow-up for the children on antiretrovirals — much closer to home. Down referral is also necessary if the Shezi clinic wants to keep putting more children on treatment. Otherwise, management of the increasing numbers of patients on ART would quickly saturate all the clinic’s recently “freed up” capacity.

But this is only a first step. “We have to turn this condition into a primary health care condition,” said Dr. Venter. “We have to get to the stage where people are starting antiretrovirals at the primary health care level. This is one of the big challenges in the next two or three years.”

Conclusion

“It is too early to call this programme a success or failure but the clock is ticking and we’re counting in lives,” said Dr. Venter in conclusion. “We have to rededicate ourselves to again and again to work twice as hard and twice as smart to make the programme work -- it is an opportunity and a responsibility.”

References

Barker PM, McCannon J, Venter WDF, Mmbara NW. Managing HIV as a chronic disease: Using interactive data collection to improve clinical care. South Africa Journal of HIV Medicine. 2005.

Black V. Establishing an Antiretroviral Clinic within the Antenatal Clinics. 2nd South African AIDS Conference, Satellite Session: The United States Presidents Emergency Plan for AIDS Relief Satellite Conference, June 2005.

Moultrie H et al. Implementation of a chronic care model of treatment to improve quality of health care for HIV-infected children at the Harriet Shezi Clinic. 2nd South African AIDS Conference, Satellite Session: Treatment and research options for pediatric HIV infection in South Africa, June 2005.

Ndjeka, NO and Manhaeve, CIJ. Antiretroviral therapy at the Primary Health care Level offered by the HIV Prevention Group in BelaBela, Limpopo. 2nd South African AIDS Conference, Abstract 630, June 2005.

Venter F. “A critical evaluation of the South African Antiretroviral Program” 2nd South African AIDS Conference, June 2005.

Online resources:

Many of the plenary presentations and the rapporteur sessions from the 2nd South African AIDS Conference are now viewable online at http://www.sa-aidsconference.com/

The website for the Institute for Healthcare Improvement has some good materials on its work in South Africa. In particular, see Dr. Pierre Barker’s “blog” and the IHI Start Up Strategy in South Africa: http://www.ihi.org/IHI/Topics/DevelopingCountries/Africa/

News Headlines

Nevirapine lingers for two weeks after mums give birth

http://www.aidsmap.com/en/news/3DF95510-9286-4170-BD12-1824AA87E562.asp

Dutch researchers this week confirmed the Thai findings reported last year, showing that women exposed to a single dose of nevirapine (Viramune)may still have detectable levels of the drug in their blood more than two weeks later. The authors of the study, published in the August 1st edition of the Journal of Acquired Immune Deficiency Syndromes, say that short three to five day courses of antiretroviral treatment after delivery may not be sufficient to prevent all mothers from developing nevirapine resistance.

Monkeys exposed to alcohol have higher SHIV viral load

http://www.aidsmap.com/en/news/07BA5833-7338-4113-A26D-CBA69954B09E.asp

Macaques infected with the simian immunodeficiency virus and exposed to alcohol in their drinking water had significantly higher SHIV viral load after 18 to 24 weeks of alcohol exposure, according to findings from a small study published in the August 1st edition of the Journal of Acquired Immune Deficiency Syndromes.

South Africa: keeping mum alive is the best medicine

http://www.aidsmap.com/en/news/CEC6D259-25EB-4A0C-9692-C39C88B183D6.asp

It is tempting to call it a "no brainer": the idea that attempts to prevent transmission of HIV from mothers to children should be matched by initiatives to keep these mothers alive after they give birth. For all this, efforts in South Africa to prioritise the health of HIV-positive mothers have fallen short over past years, although there are signs that government may be starting to give the matter the attention it deserves.

South Africa: Nurses to fill the gaps

http://www.aidsmap.com/en/news/994E71BE-0BE2-4A8E-9C2C-E7342FC10367.asp

South Africa continues to lose skilled healthcare professionals as it rolls out the national treatment programme, leaving severe shortages in an already overstretched public health system.

Burkina Faso aims to put 30,000 on ARVs by 2010

http://www.aidsmap.com/en/news/B5E8F0D6-23D2-4CED-96DC-1F8CBAE43FF2.asp

The government of Burkina Faso has announced plans to double the number of people living with AIDS on subsidised antiretroviral (ARV) treatment to 10,000 by the end of this year and increase the number of people receiving the life-enhancing drugs to more than 30,000 by 2010.

India, China or Brazil - who will produce the second line ARVs?

http://www.aidsmap.com/en/news/24B33FA6-89CB-42BA-880F-18D774FF85D6.asp

Reproduced from Health and Development Networks SEA-AIDS Forum coverage of the 7th International Conference on AIDS in Asia and the Pacific

The rapid scale-up of antiretroviral (ARV) treatment programs around the Asian region is underway. However, with that rapid scale-up will come the inevitable growth of drug resistance and the need for second line ARV therapy. Much of the developing world currently depends on Indian generics to support its treatment scale-up, but with the recently revised Indian patent law restricting the production of generic ARVs, treatment advocates now warn of a looming 'ARV access crisis' that could sabotage efforts to control the epidemic.

Brazil reaches 11th hour deal on drug patent

http://www.aidsmap.com/en/news/83C0EF16-F9EC-4A9C-8200-5E07E99CB38D.asp

The Brazilian government has reached a deal with Abbott Laboratories that will ensure cheaper supplies of lopinavir/ritonavir (Kaletra) without beginning the production of a generic version of the drug in Brazil, the country’s health minister announced on Friday.

Increased vaginal shedding of HIV in pregnant women infected with subtype C

http://www.aidsmap.com/en/news/E571D777-97B7-404D-80D3-31F231FF3568.asp?hp=1

Pregnant women infected with subtype C of HIV-1 shed more of the virus in their vaginal mucosa, than women infected with subtypes A or D, according to a study conducted in Kenya and published in the August 1st edition of the Journal of Infectious Diseases. However, the investigators found that the rate of mother-to-baby transmission of HIV was comparable between women infected with subtypes A, C and D.

Methadone included, tenofovir excluded, from new WHO essential drugs list

http://www.aidsmap.com/en/news/CB2E38F0-1580-4011-8383-1F31413F8A45.asp?hp=1

Methadone and the opiate substitute buprenorphine have been added to the World Health Organization’s Essential Drugs list, it was announced on Friday, ending nearly two years of lobbying by treatment advocates for inclusion of the drugs on the list.

3 million on treatment target unlikely to be met by end of 2005, says WHO

http://www.aidsmap.com/en/news/545DE501-06E1-4DB8-91E4-14853F0BF7D0.asp?hp=1

The ambitious global target to enrol three million people on antiretroviral treatment by the end of 2005 is not likely to be reached until midway through 2006, the World Health Organisation (WHO) admitted today on the release of its `3 x 5` progress report.

Bristol Myers Squibb to cut price of two HIV drugs for children

http://www.aidsmap.com/en/news/9DBAAFD9-5193-4260-97A4-56758EB66012.asp?hp=1

Bristol Myers Squibb announced yesterday that is is cutting the cost of its paediatric formulations of two drugs – stavudine (Zerit) and didanosine (Videx) – in least developed countries.

Generic efavirenz approved for PEPFAR use but 4 African countries reject US drug standard

http://www.aidsmap.com/en/news/B7AB90A8-C770-4428-B43B-FB425F01AA23.asp?hp=1

The United States Food and Drug Administration (FDA) announced on Friday that it had granted tentative approval for efavirenz tablets manufactured by Aurobindo Pharma Ltd of Hyderabad, India. This product is the first tentatively approved generic version of efavirenz.

Brazil warns of generic Kaletra unless Abbott halves price within 10 days

http://www.aidsmap.com/en/news/312ABE3A-7E19-47E8-81A1-B06F6F7E805C.asp?hp=1

In a bid to shave burgeoning drug budgets the Brazilian government this week issued a final ultimatum to Abbott Laboratories, manufacturer of Kaletra (lopinavir/ritonavir) yesterday: either cut the price of the drug in Brazil by 50%, or we will issue a compulsory license in ten days time so that the drug can be manufactured in Brazil more cheaply.

XIV International HIV Drug Resistance Workshop: preventing mother-to-child transmission

http://www.aidsmap.com/en/news/CCA02539-01D0-4F06-8AF2-86EFD1321473.asp?hp=1

One message from PMTCT that has come through resoundingly clear is that administering a single dose of nevirapine (NVP, Viramune) can lead to drug resistance in both the mother and the child. This is because nevirapine may persist for up to 14-21 days in the mother’s body after a single dose. Dwindling drug levels create the ideal environment for the selection of drug-resistant viruses, which require only one mutation to occur for high-level nevirapine resistance to emerge. Although single dose nevirapine reduces the rate of HIV transmission, other strategies that supplement single dose nevirapine with zidovudine (Retrovir) or zidovudine/lamivudine result in lower rates of nevirapine resistance.

Key take-home messages from the XIV International HIV Drug Resistance Workshop

http://www.aidsmap.com/en/news/FF161051-FA16-4CED-86F8-2AF8C5117000.asp?hp=1

The XIV International HIV Drug Resistance Workshop took place between June 7 and 11 in Quebec City, Canada. At this year’s workshop there was evidence of a number of developments in areas, including prevention of mother-to-child transmission (PMTCT); epidemiology – in particular, the issue of drug transmission and its public health consequences; further understanding of the mechanisms of action of entry inhibitors, and finally some new insights into subtype variation.

XIV International HIV Drug Resistance Workshop: Epidemiology

http://www.aidsmap.com/en/news/F19BC49D-2050-44D4-A77D-20A66396D065.asp?hp=1

An interesting, albeit inconclusive, theme that emerged at the workshop was the detection of minor viral populations and what that means for our understanding of epidemiology, the transmission of drug resistance including multi-drug resistant strains and their potential impact on future treatment outcomes.

Two generic versions of nevirapine approved for PEPFAR use

http://www.aidsmap.com/en/news/D114D0C5-A1CE-43B5-9D81-16B030AB8A65.asp?hp=1

The United States Food and Drug Administration (FDA) has announced tentative approval of two applications for nevirapine tablets manufactured by Ranbaxy Laboratories and Aurobindo Pharma Limited, both based in India. These are the first generic versions of nevirapine tablets to be approved for purchase by the President's Emergency Plan for AIDS Relief (PEPFAR).

Lipid-lowering drugs better at lowering blood fats caused by protease inhibitors than switching to NNRTI

http://www.aidsmap.com/en/news/5E12C1FA-B03E-42B0-A206-A6B680120222.asp?hp=1

Managing hyperlypidaemia caused by protease inhibitors (PIs) with pravastatin (Lipostat) or bezafibrate (Bezalip) is significantly more effective than changing treatment to a non-nucleoside reverse transcriptase inhibitor (NNRTI), according to an Italian study published in the July 1st edition of AIDS. The investigators also found comparable immune and virological outcomes between patients taking lipid lowering drugs and those switching to an NNRTI. In addition they established that individuals taking pravastatin or bezafibrate were no more likely than those changing their highly active antiretroviral treatment (HAART) regimen to experience side-effects.

Duration of ddI treatment and dose risk factors for CD4 loss in patients taking ddI/tenofovir

http://www.aidsmap.com/en/news/755E4DD0-7123-44B9-84A2-09F5268D7F9B.asp?hp=1

Duration of ddI (Videx) therapy and ddI dose are risk factors for the loss of CD4 T-cells in patients with a controlled viral load taking a highly active antiretroviral therapy (HAART) combination including ddI and tenofovir (Viread), according to a French study published in the July 1st edition of AIDS. The investigators believe that the reason could be a build up of toxins in CD4 T-cells caused during the metabolising of ddI.

Cotrimoxazole prophylaxis for people with HIV reduces illness and death in other family members too

http://www.aidsmap.com/en/news/DE064085-673D-4553-9CB3-800AACF09849.asp?hp=1

Cotrimoxazole prophylaxis appears to provide an indirect benefit to HIV-negative members of the household if an HIV-positive person is taking it, a prospective study from Uganda shows. The findings, published in the July 1st edition of the journal AIDS, show that children under the age of ten were nearly two-thirds less likely to die if a family member was receiving cotrimoxazole; all family members were less likely to become sick or die, and malarial parasitamia declined among HIV-negative family members too.

South African HIV prevalence steadily rising; researchers investigate why some communities are harder hit

http://www.aidsmap.com/en/news/871A9B2F-7349-4405-974C-5ADF02D1844F.asp?hp=1

Three studies presented last Wednesday at the 2nd South African AIDS Conference Durban show that there is room for improvement in the country’s “HIV intelligence gathering” (HIV surveillance). Better, more current data that includes information on risk behaviours could help the country develop more targeted and effective prevention.

US FDA approves second Indian generic HIV drug for use by PEPFAR

http://www.aidsmap.com/en/news/8F7845C9-44A3-40AE-B99A-F580D301141D.asp?hp=1

The United States Food and Drug Administration (FDA) announced yesterday that it has granted a tentative approval for generic lamivudine tablets, 150 mg and 300 mg, manufactured by Aurobindo Pharma Ltd., Hyderabad, India.

One in eight South African teachers may be HIV-positive

http://www.aidsmap.com/en/news/620132E6-9AD7-40DC-9371-EEBB82147BAB.asp?hp=1

Around one in eight South African teachers may be HIV-positive and South Africa risks losing at least 4,000 teachers a year for the rest of the decade unless more active measures are taken to diagnose HIV amongst the profession and provide treatment, according to research presented last week at the Second South African AIDS Conference. Changes in working conditions for rural teachers could also have a big impact on the infection rate, researchers argue.

South Africa must declare war on AIDS, but respect human rights

http://www.aidsmap.com/en/news/AE4EC58F-77C0-4161-B11D-077A7950BD77.asp?hp=1

Speakers at the Second South African AIDS Conference last week warned that unless South Africa adopted a war footing against HIV whilst maintaining vigilance on human rights, any limited gains in the struggle against AIDS in South Africa could be swiftly eroded.

Traditional risk factors, not PIs or HIV cause hardening of arteries in US study

http://www.aidsmap.com/en/news/1D7160AF-17B8-434F-946B-8E0056CBC9C0.asp?hp=1

Traditional risk factors for heart disease, not treatment with a protease inhibitor, are associated with hardening of the carotid artery, according to a US study published in the June 10th edition of AIDS. This finding is in contrast to some earlier studies, but the investigators stress the strength of their study, particularly their matching of HIV-positive patients taking a protease inhibitor with HIV-positive patients not on protease inhibitor therapy and HIV-negative controls according to traditional risk factors for cardiovascular disease.